Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Payables: 2019-2024

Historic Payables for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $11.5 million.

  • Nurix Therapeutics' Payables rose 119.73% to $8.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $34.4 million, marking a year-over-year increase of 80.80%. This contributed to the annual value of $11.5 million for FY2024, which is 79.38% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Payables of $11.5 million as of FY2024, which was up 79.38% from $6.4 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Payables peaked at $11.5 million during FY2024, and registered a low of $3.4 million during FY2020.
  • For the 3-year period, Nurix Therapeutics' Payables averaged around $7.6 million, with its median value being $6.4 million (2023).
  • Per our database at Business Quant, Nurix Therapeutics' Payables spiked by 113.52% in 2020 and then decreased by 23.85% in 2022.
  • Over the past 5 years, Nurix Therapeutics' Payables (Yearly) stood at $3.4 million in 2020, then soared by 94.90% to $6.7 million in 2021, then fell by 23.85% to $5.1 million in 2022, then increased by 26.40% to $6.4 million in 2023, then soared by 79.38% to $11.5 million in 2024.